Edwards Lifesciences Corporation (NYSE:EW) Short Interest Update

Edwards Lifesciences Corporation (NYSE:EW) was the recipient of a significant growth in short interest in the month of December. As of December 31st, there was short interest totaling 7,138,485 shares, a growth of 26.6% from the December 15th total of 5,640,466 shares. Based on an average daily trading volume, of 2,791,483 shares, the short-interest ratio is presently 2.6 days. Approximately 1.2% of the company’s stock are short sold. Approximately 1.2% of the company’s stock are short sold. Based on an average daily trading volume, of 2,791,483 shares, the short-interest ratio is presently 2.6 days.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW traded down $0.10 during midday trading on Friday, hitting $84.39. The stock had a trading volume of 3,454,396 shares, compared to its average volume of 2,817,066. Edwards Lifesciences has a 1 year low of $65.94 and a 1 year high of $87.89. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. The stock has a 50 day moving average price of $85.12 and a two-hundred day moving average price of $80.59. The company has a market capitalization of $48.97 billion, a PE ratio of 36.38, a P/E/G ratio of 3.39 and a beta of 0.95.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The firm had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter last year, the firm earned $0.67 earnings per share. The firm’s revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, equities analysts predict that Edwards Lifesciences will post 2.45 earnings per share for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction on Friday, January 9th. The shares were sold at an average price of $85.70, for a total transaction of $87,328.30. Following the completion of the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,885,571.40. The trade was a 4.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Scott B. Ullem sold 7,700 shares of the stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total value of $650,419.00. Following the completion of the transaction, the chief financial officer directly owned 39,898 shares in the company, valued at $3,370,184.06. This trade represents a 16.18% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 57,824 shares of company stock valued at $4,863,323 over the last 90 days. 1.29% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Edwards Lifesciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Brighton Jones LLC acquired a new stake in shares of Edwards Lifesciences during the 4th quarter valued at approximately $266,000. Pallas Capital Advisors LLC increased its stake in Edwards Lifesciences by 28.8% in the 2nd quarter. Pallas Capital Advisors LLC now owns 3,952 shares of the medical research company’s stock valued at $309,000 after purchasing an additional 884 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd raised its holdings in Edwards Lifesciences by 2.1% during the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 73,781 shares of the medical research company’s stock worth $5,770,000 after purchasing an additional 1,521 shares during the last quarter. Wedmont Private Capital raised its holdings in Edwards Lifesciences by 22.6% during the second quarter. Wedmont Private Capital now owns 12,090 shares of the medical research company’s stock worth $933,000 after purchasing an additional 2,230 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its position in Edwards Lifesciences by 111.9% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 163,202 shares of the medical research company’s stock worth $12,532,000 after purchasing an additional 86,186 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on EW shares. UBS Group reiterated a “neutral” rating and set a $95.00 price target (up from $92.00) on shares of Edwards Lifesciences in a research note on Monday, January 12th. Citigroup reissued a “buy” rating and issued a $101.00 target price (up from $96.00) on shares of Edwards Lifesciences in a report on Thursday, December 11th. Robert W. Baird set a $90.00 target price on Edwards Lifesciences in a research report on Monday, January 12th. Wells Fargo & Company set a $100.00 price target on Edwards Lifesciences in a research report on Thursday, December 18th. Finally, Evercore ISI reiterated an “outperform” rating and issued a $94.00 price objective on shares of Edwards Lifesciences in a research note on Monday, January 5th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $96.45.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.